Global Circular Tumor Cell (CTC) Diagnostics Market (By Technology – CTC Enrichment, CTC Detection and CTC Diagnosis; By Application – Breast Cancer, Lung Cancer, ColoRectal Cancer, Prostrate Cancer and Others, By End-User– Biotechnological Research Centers, Hospitals & Clinics, Pharmaceuticals, Academic Research Institutions) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2017 – 2025

November 2017 | 156 pages | ID: G6843FA8D24EN
Sheer Analytics and Insights Private Limited

Abstracts

The report covers the analysis and forecast of the circulating tumor cell (CTC) diagnostics market on global as well as regional level. The study provides historic data of 2016 along with the forecast for the period between 2017 and 2025 based on revenue (US$ Bn).

The study provides a detailed view of the circulating tumor cell (CTC) diagnostics market, by segmenting it based on, technology, application, end-user and regional demand. The technology segment includes CTC enrichment, CTC detection and CTC analysis. The CTC enrichment section can be sub segmented into microchips, single spiral micro channel, positive (both in-vivo and ex-vivo types) and negative selection; while on the other hand, CTC detection procedure consists of molecular-based (RNA) technologies, optical-based flow cytometry, EPISPOT in-vitro cell culture, in-vitro cell invasion assay and different xenotransplantation models.

Based on application, the market can be classified into different kinds of cancer viz. breast cancer, lung cancer, colorectal cancer, prostate cancer and others (skin cancer, pancreatic cancer and ovarian cancer).

End-User segment includes biotechnological research centers, hospitals and clinics, pharmaceuticals and academic research institutions.

Regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Market dynamics for each region has been provided in the report.

Contents

1 INTRODUCTION

1.1 MARKET SEGMENTATION

2 RESEARCH METHODOLOGY

2.1 ECOSYSTEM OF MARKET
2.2 TOP-DOWN APPROACH
2.3 BOTTOM-UP APPROACH
2.4 ASSUMPTIONS

3 EXECUTIVE SUMMARY

3.1 GLOBAL CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS MARKET SNAPSHOT
3.2 GLOBAL CTC DIAGNOSTICS MARKET REVENUE, 2017 – 2025 (US$ BN)

4 MARKET OVERVIEW

4.1 INTRODUCTION
4.2 KEY TRENDS ANALYSIS
4.3 PRODUCT DEVELOPMENT AND DIVERSIFICATION ANALYSIS
4.4 PORTERS FIVE FORCE ANALYSIS
4.5 VALUE CHAIN ANALYSIS
4.6 COMPETITIVE LANDSCAPE
4.7 COMPANY MARKET SHARE ANALYSIS, %, 2016
4.8 EXPANSION STRATEGIES ADOPTED BY LEADING PLAYERS

5 GLOBAL CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS MARKET, BY TECHNOLOGY

5.1 OVERVIEW
5.2 GLOBAL CTC DIAGNOSTICS MARKET FOR CTC (TUMOR) ENRICHMENT, VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
5.3 GLOBAL CTC DIAGNOSTICS MARKET FOR CTC (TUMOR) DETECTION, VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
5.4 GLOBAL GLOBAL CTC DIAGNOSTICS MARKET FOR CTC ANALYSIS; VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)

6 GLOBAL CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS MARKET, BY APPLICATION

6.1 OVERVIEW
6.2 GLOBAL CTC DIAGNOSTICS MARKET FOR BREAST CANCER, VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
6.3 GLOBAL GLOBAL CTC DIAGNOSTICS MARKET FOR LUNG CANCER, VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
6.4 GLOBAL GLOBAL CTC DIAGNOSTICS MARKET FOR COLORECTAL CANCER, VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
6.5 GLOBAL GLOBAL CTC DIAGNOSTICS MARKET FOR PROSTATE CANCER, VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
6.6 GLOBAL GLOBAL CTC DIAGNOSTICS MARKET FOR OTHERS (SKIN CANCER, PANCREATICCANCER & OVARIAN CANCER) CANCER, VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)

7 GLOBAL CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS MARKET, BY END-USER

7.1 OVERVIEW
7.2 GLOBAL CTC DIAGNOSTICS MARKET FOR BIOTECHNOLOGICAL RESEARCH CENTERS, VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
7.3 GLOBAL GLOBAL CTC DIAGNOSTICS MARKET FOR , HOSPITALS & CLINICS, VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
7.4 GLOBAL GLOBAL CTC DIAGNOSTICS MARKET FOR PHARMACEUTICALS , VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
7.5 GLOBAL GLOBAL CTC DIAGNOSTICS MARKET FOR, ACADEMIC RESEARCH INSTITUTIONS , VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)

8 GLOBAL CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS MARKET, BY GEOGRAPHY

8.1 NORTH AMERICA
  8.1.1 MARKET DYNAMICS
    8.1.1.1 Drivers
    8.1.1.2 Restraints
    8.1.1.3 Opportunity
  8.1.2 U.S.
  8.1.3 CANADA
  8.1.4 MEXICO
8.2 EUROPE
  8.2.1 MARKET DYNAMICS
    8.2.1.1 Drivers
    8.2.1.2 Restraints
    8.2.1.3 Opportunity
  8.2.2 U.K.
  8.2.3 ITALY
  8.2.4 FRANCE
  8.2.5 GERMANY
  8.2.6 RUSSIA
  8.2.7 SPAIN
  8.2.8 REST OF EUROPE
8.3 ASIA PACIFIC
  8.3.1 MARKET DYNAMICS
    8.3.1.1 Drivers
    8.3.1.2 Restraints
    8.3.1.3 Opportunity
  8.3.2 INDIA
  8.3.3 CHINA
  8.3.4 JAPAN
  8.3.5 AUSTRALIA
  8.3.6 REST OF ASIA PACIFIC
8.4 MIDDLE EAST AND AFRICA
  8.4.1 MARKET DYNAMICS
    8.4.1.1 Drivers
    8.4.1.2 Restraints
    8.4.1.3 Opportunity
  8.4.2 GCC
  8.4.3 SOUTH AFRICA
  8.4.4 REST OF MIDDLE EAST AND AFRICA
8.5 LATIN AMERICA
  8.5.1 MARKET DYNAMICS
    8.5.1.1 Drivers
    8.5.1.2 Restraints
    8.5.1.3 Opportunity
  8.5.2 BRAZIL
  8.5.3 REST OF LATIN AMERICA

9 COMPETITIVE LANDSCAPE

9.1 OVERVIEW
9.2 NEW PRODUCT LAUNCHES

10 GLOBAL CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS MARKET, BY COMPANY

10.1 INTRODUCTION
10.2 ADNAGEN AG
  10.2.1 BUSINESS OVERVIEW
  10.2.2 PRODUCTS & SERVICES
  10.2.3 KEY STRATEGY
  10.2.4 RECENT DEVELOPMENTS
  10.2.5 SWOT ANALYSIS
  10.2.6 OUR COMPANY VIEW
10.3 ADVANCED CELL DIAGNOSTICS
  10.3.1 BUSINESS OVERVIEW
  10.3.2 PRODUCTS & SERVICES
  10.3.3 KEY STRATEGY
  10.3.4 RECENT DEVELOPMENTS
  10.3.5 SWOT ANALYSIS
  10.3.6 OUR COMPANY VIEW
10.4 AVIVA BIOSCIENCES CORP.
  10.4.1 BUSINESS OVERVIEW
  10.4.2 PRODUCTS & SERVICES
  10.4.3 KEY STRATEGY
  10.4.4 RECENT DEVELOPMENTS
  10.4.5 SWOT ANALYSIS
  10.4.6 OUR COMPANY VIEW
10.5 BIOCEPT, INC.
  10.5.1 BUSINESS OVERVIEW
  10.5.2 PRODUCTS & SERVICES
  10.5.3 KEY STRATEGY
  10.5.4 RECENT DEVELOPMENTS
  10.5.5 SWOT ANALYSIS
  10.5.6 OUR COMPANY VIEW
10.6 CELULA, INC.
  10.6.1 BUSINESS OVERVIEW
  10.6.2 PRODUCTS & SERVICES
  10.6.3 KEY STRATEGY
  10.6.4 RECENT DEVELOPMENTS
  10.6.5 SWOT ANALYSIS
  10.6.6 OUR COMPANY VIEW
10.7 CYNVENIO BIOSYSTEMS, INC.
  10.7.1 BUSINESS OVERVIEW
  10.7.2 PRODUCTS & SERVICES
  10.7.3 KEY STRATEGY
  10.7.4 RECENT DEVELOPMENTS
  10.7.5 SWOT ANALYSIS
  10.7.6 OUR COMPANY VIEW
10.8 EPIC SCIENCES, INC.
  10.8.1 BUSINESS OVERVIEW
  10.8.2 PRODUCTS & SERVICES
  10.8.3 KEY STRATEGY
  10.8.4 RECENT DEVELOPMENTS
  10.8.5 SWOT ANALYSIS
  10.8.6 OUR COMPANY VIEW
10.9 FLUXION BIOSCIENCES, INC.
  10.9.1 BUSINESS OVERVIEW
  10.9.2 PRODUCTS & SERVICES
  10.9.3 KEY STRATEGY
  10.9.4 RECENT DEVELOPMENTS
  10.9.5 SWOT ANALYSIS
  10.9.6 OUR COMPANY VIEW
10.10 MENARINI SILICON BIOSYSTEMS, INC.
  10.10.1 BUSINESS OVERVIEW
  10.10.2 PRODUCTS & SERVICES
  10.10.3 KEY STRATEGY
  10.10.4 RECENT DEVELOPMENTS
  10.10.5 SWOT ANALYSIS
  10.10.6 OUR COMPANY VIEW
10.11 NANOSTRING TECHNOLOGIES, INC.
  10.11.1 BUSINESS OVERVIEW
  10.11.2 PRODUCTS & SERVICES
  10.11.3 KEY STRATEGY
  10.11.4 RECENT DEVELOPMENTS
  10.11.5 SWOT ANALYSIS
  10.11.6 OUR COMPANY VIEW
10.12 RARECELLS, USA
  10.12.1 BUSINESS OVERVIEW
  10.12.2 PRODUCTS & SERVICES
  10.12.3 KEY STRATEGY
  10.12.4 RECENT DEVELOPMENTS
  10.12.5 SWOT ANALYSIS
  10.12.6 OUR COMPANY VIEW
10.13 VERIDEX , LLC.
  10.13.1 BUSINESS OVERVIEW
  10.13.2 PRODUCTS & SERVICES
  10.13.3 KEY STRATEGY
  10.13.4 RECENT DEVELOPMENTS
  10.13.5 SWOT ANALYSIS
  10.13.6 OUR COMPANY VIEW
10.14 VITATEX INC.
  10.14.1 BUSINESS OVERVIEW
  10.14.2 PRODUCTS & SERVICES
  10.14.3 KEY STRATEGY
  10.14.4 RECENT DEVELOPMENTS
  10.14.5 SWOT ANALYSIS
  10.14.6 OUR COMPANY VIEW